ClinicalTrials.gg
Active, not recruitingNCT07169578TRONTIER 1Updated Sep 25, 2026

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

A Phase 3 interventional study of Trontinemab and Placebo in Alzheimers Disease, sponsored by Hoffmann-La Roche. Active, not recruiting at 142 sites in 13 countries. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Updated Sep 25, 2026Now Active, not recruitingPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,101
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Alzheimer Disease by Hoffmann-La Roche — 3 open to participants now, 8 under way, 4 of them phase 3. Alzheimer Disease · Hoffmann-La Roche.

Enrollment
4th of 40
1,101 · median 247
Started
2025
with 2 others
Phase 3
14 of 40
2 open now
Registered
35th of 40
by date

Among the 40 studies in Alzheimer Disease by Hoffmann-La Roche, this one is the 4th largest by enrollment, is one of 3 that started in 2025, is one of 14 in phase 3, and was the 35th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

3 of the 40 studies in Alzheimer Disease by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Alzheimer Disease by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).

03

Conditions studied

  • Alzheimers Disease

Keywords

  • Early Alzheimers Disease
  • Mild Cognitive Impairment
  • Mild Dementia
04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willingness and ability to complete all aspects of the study (including MRI, clinical genotyping, and PET imaging or CSF as applicable) for the duration of the study. The participant should be capable of completing assessments either alone or with the help of the study partner
  • Adequate visual and auditory acuity, in the investigator's judgment, sufficient to perform the neuropsychological testing (eyewear and hearing aids are permitted)
  • Evidence of AD pathological process, as confirmed on amyloid PET scan. A CSF tau181/Aβ42 ratio may be used as an alternative option if amyloid PET is not available
  • Probable AD dementia or MCI due to AD, also known as an Alzheimer's clinical syndrome clinical Stage 3 or Stage 4
  • Screening score ≥ 22 and CDR-GS of 0.5 or 1.0
  • Participant- and/or Informant-reported history of cognitive decline with gradual onset and progression over the last 1 year before screening
  • A Repeatable Battery for the Assessment of Neuropsychological Status Delayed Memory Index (RBANS DMI) score of 85 or order
  • Availability of a "study partner" as defined by the protocol

Exclusion criteria

Exclusion Criteria:

  • Any evidence of a condition other than AD that may affect cognition
  • History or presence of cerebrovascular disease
  • History of severe, clinically significant (persistent neurologic deficit or structural brain damage) central nervous system (CNS) trauma
  • History or presence of clinically significant intracranial mass
  • MRI evidence of significant cerebral abnormalities or inability to tolerate MRI procedures or to MRI
  • Any other medical conditions (e.g., cardiovascular, hepatic, renal disease) which are not stable and adequately controlled or which in the opinion of the investigator could affect the participant's safety in the study or interfere with the study assessments
  • History of with the following exceptions: if considered to be cured; malignancies with a negligible risk of or death
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,101 participants (actual)

Study arms

  • Experimental
    Trontinemab

    Participants will receive intravenous (IV) trontinemab.

    Drug: Trontinemab

  • Placebo comparator
    Placebo

    Participants will receive IV placebo.

    Other: Placebo

Interventions

  • Participants will receive IV trontinemab.

    Also known as: RO7126209

  • OtherPlacebo

    Participants will receive IV placebo.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 72 in Clinical Dementia Rating, Sum of Boxes (CDR-SB)

    Time frame: Baseline - Week 72

Secondary outcomes

  1. Change From Baseline Through Week 72 in Alzheimer's Disease Assessment Scale-Cognition 13 (ADAS-Cog-13)

    Time frame: Baseline - Week 72

  2. Change From Baseline Through Week 72 in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) Total Score and Instrumental Score

    Time frame: Baseline - Week 72

  3. Change From Baseline Through Week 72 in Integrated Alzheimer's Disease Rating Scale (iADRS)

    Time frame: Baseline - Week 72

  4. Change From Baseline Through Week 72 in Mini-Mental State Examination (MMSE)

    Time frame: Baseline - Week 72

  5. Change From Baseline in CDR-SB

    Time frame: Baseline up to but excluding Week 72

  6. Time to Increase in Clinical Dementia Rating, Global Score (CDR-GS)

    Time frame: Baseline - Week 72

  7. Percentage of Participants With Adverse Events (AEs)

    Time frame: Baseline - Week 72

  8. Change from Baseline in C-SSRS (Columbia-Suicide Severity Rating Scale)

    Time frame: Baseline - Week 72

  9. Percentage of Participants With Amyloid-related Imaging Abnormalities (ARIA) Magnetic Resonance Imaging (MRI) Findings

    Time frame: Baseline - Week 72

  10. Percentage of Participants With Infusion-related Reactions (IRR)

    Time frame: Baseline - Week 72

  11. Percentage of Participants With Anti-drug Antibodies (ADAs) to Trontinemab

    Time frame: Baseline - Week 72

  12. Change From Baseline Through Week 72 in Brain Amyloid Load as Measured by Amyloid Positron Emission Tomography (PET) Scan

    Time frame: Baseline - Week 72

  13. Change From Baseline to Week 72 in Brain tau Load as Measured by tau PET Scan in a Subset of Participants

    Time frame: Baseline - Week 72

  14. Change From Baseline Through Week 72 in Cerebrospinal Fluid (CSF) Biomarkers of Disease p-tau181, Neurogranin, Amyloid Beta(Aβ)42, Aβ42/40 in a Subset of Participants

    Time frame: Baseline - Week 72

  15. Change From Baseline Through Week 72 in Blood Biomarkers p-tau217, Glial Fibrillar Acidic Protein (GFAP), Aβ42, Aβ42/40

    Time frame: Baseline - Week 72

07

Study locations

142 sites

Showing the first 100 of 142 sites across 13 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Feb 2028, 28 months after the start.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's planned 28 months is below that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Jun 2028 → Feb 2028 and completion Jun 2028 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Sep 12, 2025
StartActual
Sep 17, 2025
Primary completionEst.
Feb 16, 2028was Jun 2028
CompletionEst.
Feb 16, 2028was Jun 2028
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Sep 25, 2026
Sites
1 site removed
Show 1 removed
  • Sanatorio del Sur S.A. · San Miguel de Tucumán, Argentina
Sep 25, 2026
Primary completion
Jun 7, 2028→Feb 16, 2028
Sep 25, 2026
Study completion
Jun 7, 2028→Feb 16, 2028
Sep 25, 2026
Enrollment
800 (estimated)→1101 (actual)
Sep 25, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange from baselineFrom Baseline to Week 72 in Clinical Dementia Rating, Sum of Boxes (CDR-SB)Time frame: Baseline - Week 72
Sep 25, 2026
Secondary outcomes
14 edited, 1 added
What changed in the outcomes
  • EditedChange from baseline throughFrom Baseline Through Week 72 in Alzheimer's Disease Assessment Scale-Cognition 13 (ADAS-Cog-13)Time frame: Baseline - Week 72
  • EditedChange from baseline throughFrom Baseline Through Week 72 in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) total scoreTotal Score and instrumental scoreInstrumental ScoreTime frame: Baseline - Week 72
  • EditedChange from baseline throughFrom Baseline Through Week 72 in Integrated Alzheimer's Disease Rating Scale (iADRS)Time frame: Baseline - Week 72
  • EditedChange from baseline throughFrom Baseline Through Week 72 in Mini-Mental State Examination (MMSE)Time frame: Baseline - Week 72
  • EditedChange from baselineFrom Baseline in CDR-SBTime frame: Baseline up to but excluding Week 72
  • EditedTime to increaseIncrease in Clinical Dementia Rating, Global Score (CDR-GS)Time frame: Baseline - Week 72
  • EditedPercentage of participants with adverse eventsParticipants With Adverse Events (AEs)Time frame: Baseline - Week 72
  • EditedPercentage of participants with amyloidParticipants With Amyloid-related imaging abnormalitiesImaging Abnormalities (ARIA) magnetic resonance imagingMagnetic Resonance Imaging (MRI) findingsFindingsTime frame: Baseline - Week 72
  • EditedPercentage of participants with infusionParticipants With Infusion-related reactionsReactions (IRR)Time frame: Baseline - Week 72
  • EditedPercentage of participants with antiParticipants With Anti-drug antibodiesAntibodies (ADAs) to trontinemabTrontinemabTime frame: Baseline - Week 72
  • EditedChange from baseline throughFrom Baseline Through Week 72 in brain amyloid loadBrain Amyloid Load as measuredMeasured by amyloid positron emission tomographyAmyloid Positron Emission Tomography (PET) scanScanTime frame: Baseline - Week 72
  • EditedChange from baselineFrom Baseline to Week 72 in brainBrain tau loadLoad as measuredMeasured by tau PET scanScan in a subsetSubset of participantsParticipantsTime frame: Baseline - Week 72
  • EditedChange from baseline throughFrom Baseline Through Week 72 in cerebrospinal fluidCerebrospinal Fluid (CSF) biomarkersBiomarkers of diseaseDisease p-tau181, neurograninNeurogranin, Amyloid Beta(Aβ)42, Aβ42/40 in a subsetSubset of participantsParticipantsTime frame: Baseline - Week 72
  • EditedChange from baseline throughFrom Baseline Through Week 72 in blood biomarkersBlood Biomarkers p-tau217, glial fibrillar acidic proteinGlial Fibrillar Acidic Protein (GFAP), Aβ42, Aβ42/40Time frame: Baseline - Week 72
  • AddedChange from Baseline in C-SSRS (Columbia-Suicide Severity Rating Scale)Time frame: Baseline - Week 72
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Recruiting→Active, not recruiting
    1 site removed
    Show 1 removed
    • Sanatorio del Sur S.A. · San Miguel de Tucumán, Argentina
    Primary completion Jun 7, 2028→Feb 16, 2028
    Study completion Jun 7, 2028→Feb 16, 2028
    Enrollment 800 (estimated)→1101 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange from baselineFrom Baseline to Week 72 in Clinical Dementia Rating, Sum of Boxes (CDR-SB)Time frame: Baseline - Week 72
    Secondary outcomes 14 edited, 1 added
    What changed in the outcomes
    • EditedChange from baseline throughFrom Baseline Through Week 72 in Alzheimer's Disease Assessment Scale-Cognition 13 (ADAS-Cog-13)Time frame: Baseline - Week 72
    • EditedChange from baseline throughFrom Baseline Through Week 72 in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) total scoreTotal Score and instrumental scoreInstrumental ScoreTime frame: Baseline - Week 72
    • EditedChange from baseline throughFrom Baseline Through Week 72 in Integrated Alzheimer's Disease Rating Scale (iADRS)Time frame: Baseline - Week 72
    • EditedChange from baseline throughFrom Baseline Through Week 72 in Mini-Mental State Examination (MMSE)Time frame: Baseline - Week 72
    • EditedChange from baselineFrom Baseline in CDR-SBTime frame: Baseline up to but excluding Week 72
    • EditedTime to increaseIncrease in Clinical Dementia Rating, Global Score (CDR-GS)Time frame: Baseline - Week 72
    • EditedPercentage of participants with adverse eventsParticipants With Adverse Events (AEs)Time frame: Baseline - Week 72
    • EditedPercentage of participants with amyloidParticipants With Amyloid-related imaging abnormalitiesImaging Abnormalities (ARIA) magnetic resonance imagingMagnetic Resonance Imaging (MRI) findingsFindingsTime frame: Baseline - Week 72
    • EditedPercentage of participants with infusionParticipants With Infusion-related reactionsReactions (IRR)Time frame: Baseline - Week 72
    • EditedPercentage of participants with antiParticipants With Anti-drug antibodiesAntibodies (ADAs) to trontinemabTrontinemabTime frame: Baseline - Week 72
    • EditedChange from baseline throughFrom Baseline Through Week 72 in brain amyloid loadBrain Amyloid Load as measuredMeasured by amyloid positron emission tomographyAmyloid Positron Emission Tomography (PET) scanScanTime frame: Baseline - Week 72
    • EditedChange from baselineFrom Baseline to Week 72 in brainBrain tau loadLoad as measuredMeasured by tau PET scanScan in a subsetSubset of participantsParticipantsTime frame: Baseline - Week 72
    • EditedChange from baseline throughFrom Baseline Through Week 72 in cerebrospinal fluidCerebrospinal Fluid (CSF) biomarkersBiomarkers of diseaseDisease p-tau181, neurograninNeurogranin, Amyloid Beta(Aβ)42, Aβ42/40 in a subsetSubset of participantsParticipantsTime frame: Baseline - Week 72
    • EditedChange from baseline throughFrom Baseline Through Week 72 in blood biomarkersBlood Biomarkers p-tau217, glial fibrillar acidic proteinGlial Fibrillar Acidic Protein (GFAP), Aβ42, Aβ42/40Time frame: Baseline - Week 72
    • AddedChange from Baseline in C-SSRS (Columbia-Suicide Severity Rating Scale)Time frame: Baseline - Week 72
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07169578
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 12, 2025
Start date
Sep 17, 2025
Primary completion
Feb 16, 2028 (estimated)
Completion
Feb 16, 2028 (estimated)
Last update
Sep 25, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trontinemab

Start the discussion